Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.52 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.48 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886683 | 0.82 | ALDH1A1 (0.58) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL3705899 | 0.78 | ALDH1A1 (0.54) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL63857 | 0.76 | NAPRT (0.58) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL1745778 | 0.76 | NNMT (0.52) | HSD17B10KDM4ECYP2C19POLBTSHR | |
| SCHEMBL13160131 | 0.76 | CA5A (0.44) | ALDH1A1HSD17B10KDM4EALOX15P4HA1 | |
| SCHEMBL4600260 | 0.76 | ALDH1A1 (0.52) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL16749632 | 0.76 | ALDH1A1 (0.52) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL186175 | 0.76 | GABRP (0.58) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL5660197 | 0.76 | P4HA1 (0.56) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL29345465 | 0.76 | ALDH1A1 (0.52) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109467536-B | Synthesis method of 2-chloro/hydroxypyrimidine-5-carboxylic acid | 沧州普瑞东方科技有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-109467536-A | 2- chlorine/hydroxy pyrimidine -5- carboxylic acid synthetic method | 沧州普瑞东方科技有限公司 | 2019-03-15 | — | — | CN | claimed |
| US-20080119651-A1 | one pot reaction without isolating intermediates; reacting oxoalkonate with urea, trimethyl orthoformate in methanol or ethanol to yield a 2-acyl-3-ureidoacrylate, reacting intermediate with 2-hydroxypyrimidine-5-carboxylate in presence of alkali alkoxide, convering it to halo compds. with PO2Cl or SOCl2 | LONZA AG (CH) | 2008-05-22 | — | — | US | claimed |
| EP-1809609-B1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2008-04-16 | — | — | EP | claimed |
| EP-1809609-A1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2007-07-25 | — | — | EP | claimed |
| WO-2006048297-A1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2006-05-11 | — | — | WO | claimed |
| US-20260001994-A1 | HIGH-MOLECULAR COMPOUND, MOLDING COMPOSITION, FILM AND CAPACITOR | PANASONIC IP MAN CO LTD (JP) | 2026-01-01 | — | — | US | disclosed |
| CN-119110816-A | Polymer compound, molding composition, film, and capacitor | 松下知识产权经营株式会社 | 2024-12-10 | — | — | CN | disclosed |
| WO-2023248874-A1 | POLYMER COMPOUND, COMPOSITION FOR MOLDING, FILM AND CAPACITOR | パナソニックＩＰマネジメント株式会社 | 2023-12-28 | — | — | WO | disclosed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11261197-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| EP-1809609-B1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| CN-101056863-A | Process for the production of pyrimidine-5-carboxylates | LONZA AG (CH) | 2007-10-17 | — | — | CN | disclosed |
| EP-1809609-A1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| EP-1809609-A1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048297-A1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048297-A1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| CN-1660851-A | Ramification of water-soluble camptothecin and preparation method | DONGBEI FOREST UNIV (CN) | 2005-08-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119651-A1 | one pot reaction without isolating intermediates; reacting oxoalkonate with urea, trimethyl orthoformate in methanol or ethanol to yield a 2-acyl-3-ureidoacrylate, reacting intermediate with 2-hydroxypyrimidine-5-carboxylate in presence of alkali alkoxide, convering it to halo compds. with PO2Cl or SOCl2 | HPD, DCTD, POLD1 | ALDH1A1 582/4885HSD17B10 1682/4885KDM4E 1815/4885 |
| US-11261197-B2 | Neprilysin inhibitors | MME, REN, ACE | ALDH1A1 2644/4885HSD17B10 3448/4885KDM4E 2334/4885 |
| US-20260001994-A1 | HIGH-MOLECULAR COMPOUND, MOLDING COMPOSITION, FILM AND CAPACITOR | CCRL2, CBR1, CCR1 | ALDH1A1 2040/4885HSD17B10 824/4885KDM4E 1777/4885 |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ALDH1A1 2634/4885HSD17B10 3390/4885KDM4E 2402/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | ALDH1A1 2644/4885HSD17B10 3448/4885KDM4E 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.